SCHEMBL5599690

SCHEMBL5599690

O=C1OC(c2cc3cc(Cl)ccc3o2)=NC12CCCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.46
KDM4E B2RXH2 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GPR35 Q9HC97 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 3/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.39
GAA P10253 1/20 0.39
ESR1 P03372 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840645 0.83 HPGD (0.41) MAOBKDM4EL3MBTL1GPR35ALDH1A1
SCHEMBL1841462 0.74 ALDH1A1 (0.46) MAOBKDM4EL3MBTL1ALDH1A1KMT2A
SCHEMBL14231749 0.70 MAOB (0.59) MAOBKDM4EL3MBTL1GPR35ALDH1A1
SCHEMBL1836773 0.67 ALDH1A1 (0.42) KDM4EL3MBTL1ALDH1A1HSD17B10KMT2A
SCHEMBL1837077 0.66 ALDH1A1 (0.44) ALDH1A1KMT2ANPC1RAB9ATSHR
SCHEMBL1840993 0.65 ALDH1A1 (0.43) KDM4EALDH1A1HSD17B10KMT2ANPC1
SCHEMBL1842348 0.65 DYRK1A (0.44) ALDH1A1CA12CA2
SCHEMBL1843106 0.64 ALDH1A1 (0.45) KDM4EALDH1A1KMT2ANPC1RAB9A
SCHEMBL1839545 0.64 ALDH1A1 (0.40) KDM4EALDH1A1
SCHEMBL1836785 0.64 ALDH1A1 (0.45) KDM4EALDH1A1CYP1A2HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273856-B2 Linear basic compounds having NK-2 antagonist activity and formulations thereof MENARINI RICERCHE S.P.A. (IT) 2007-09-25 US disclosed
EP-1442050-B1 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI SAS (IT) 2006-09-13 EP disclosed
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259930-A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof BDKRB2, BDKRB1, TACR2 MAOB 1183/4885KDM4E 3285/4885L3MBTL1 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.